A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-08-02
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose escalation and dose expansion study to evaluate the safety,
tolerability, pharmacokinetics, and preliminary efficacy of RGT-264 as monotherapy in
subjects with advanced solid tumors.